Doptelet

Active Ingredient(s): Avatrombopag Maleate
FDA Approved: * May 21, 2018
Pharm Company: * AKARX INC
Category: Blood Volume

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Doptelet Overview

Avatrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in adult patients who are to undergo a planned medical or dental procedure. It was approved by the Food and Drug Administration in May 21, 2018.[1] References ^ [1]FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing ...

Read more Doptelet Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avatrombopag

Recent Doptelet Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Avatrombopag Maleate
  • Tablet: 20mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Doptelet: (1 result)

Sorted by National Drug Code
  • 71369-020 Doptelet 20 mg Oral Tablet, Film Coated by Akarx, Inc.

Other drugs which contain Avatrombopag Maleate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 September 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA